GlobeNewswire Inc | Nov 9, 2021 07:30AM EST

November 09, 2021

NEW YORK, Nov. 09, 2021 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced that Michael S. Weiss, the Companys Chairman and Chief Executive Officer, will participate in a fireside chat during the B. Riley Securities Fall 2021 Growth Biotech Best Ideas Virtual Series, taking place on Thursday November 11, 2021, at 12:00 PM ET.

A live webcast of this presentation will be available on the Events page, located within the Investors & Media section, of the Companys website at http://ir.tgtherapeutics.com/events. A replay of the webcast will be available on TGs website following the event.

ABOUT TG THERAPEUTICS, INC.TG Therapeuticsis a fully-integrated, commercial stage biopharmaceutical company focused on the acquisition, development and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. In addition to an active research pipeline including five investigational medicines across these therapeutic areas, TG has received accelerated approval from theU.S.FDA for UKONIQ(umbralisib), for the treatment of adult patients with relapsed/refractory marginal zone lymphoma who have received at least one prior anti-CD20-based regimen and relapsed/refractory follicular lymphoma who have received at least three prior lines of systemic therapies. Currently, the Company has three programs in Phase 3 development for the treatment of patients with relapsing forms of multiple sclerosis (RMS) and patients with chronic lymphocytic leukemia (CLL) and several investigational medicines in Phase 1 clinical development.For more information, visitwww.tgtherapeutics.com, and follow us on Twitter@TGTherapeuticsandLinkedin.

UKONIQ is a registered trademark of TG Therapeutics, Inc.

CONTACT: Investor Relations Email: ir@tgtxinc.com Telephone: 1.877.575.TGTX (8489), Option 4 Media Relations: Email: media@tgtxinc.com Telephone: 1.877.575.TGTX (8489), Option 6